Compare Sezzle Inc (SEZL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sezzle Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Sezzle Inc trades at $118.51 (market cap $3.99B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Sezzle Inc nearer its low. Which is the better fit depends on your goals.
| SEZL | XBI | |
|---|---|---|
Market Cap | $3.99B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $188.55 | $169.55 |
52-Week Low | $50.97 | $93.43 |
Enterprise Value | $4.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SEZL trades at $118.35, down 1.85% on the day, with technical indicators showing bearish momentum. The company demonstrates strong fundamentals with 30.35% net income margin and consistent earnings beats in recent quarters. Recent business developments include merchant network expansion with Gymshark and Debenhams Group, while analyst consensus remains bullish with a $161.17 price target representing 36% upside potential.
SEZL presents a compelling growth story with robust profitability metrics and expanding market presence, though technical weakness and high valuation multiples warrant caution. The stock offers significant upside based on analyst targets but faces execution risks in competitive fintech landscape and potential market volatility.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
